Literature DB >> 3062140

Sample size considerations for studies comparing survival curves using historical controls.

D O Dixon1, R Simon.   

Abstract

Formulas are derived for determination of the number of patients needed in a prospective comparison of survival curves, when the control group patients have already been followed for some period. Although an explicit formula for the required sample size is not available, the computing is straightforward, and tables of examples are presented. Situations are described when one might need to allocate some new patients to the control group, rather than exclusively to the experimental group.

Entities:  

Mesh:

Year:  1988        PMID: 3062140     DOI: 10.1016/0895-4356(88)90025-x

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  22 in total

1.  A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Authors:  Fariba Navid; Victor M Santana; Michael Neel; M Beth McCarville; Barry L Shulkin; Jianrong Wu; Catherine A Billups; Shenghua Mao; Vinay M Daryani; Clinton F Stewart; Michelle Kunkel; Wendene Smith; Deborah Ward; Alberto S Pappo; Armita Bahrami; David M Loeb; Jennifer Reikes Willert; Bhaskar N Rao; Najat C Daw
Journal:  Int J Cancer       Date:  2017-07-03       Impact factor: 7.396

2.  Calculating sample size in trials using historical controls.

Authors:  Song Zhang; Jing Cao; Chul Ahn
Journal:  Clin Trials       Date:  2010-06-23       Impact factor: 2.486

3.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

Review 4.  A comparison of phase II study strategies.

Authors:  Sally Hunsberger; Yingdong Zhao; Richard Simon
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

5.  Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.

Authors:  Jaffer A Ajani; Kathryn Winter; Ritsuko Komaki; David P Kelsen; Bruce D Minsky; Zhongxing Liao; Jeffrey Bradley; Mitchel Fromm; David Hornback; Christopher G Willett
Journal:  J Clin Oncol       Date:  2008-06-23       Impact factor: 44.544

6.  Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.

Authors:  Christopher H Crane; Kathryn Winter; William F Regine; Howard Safran; Tyvin A Rich; Walter Curran; Robert A Wolff; Christopher G Willett
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

7.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.

Authors:  H Ian Robins; Anne O'Neill; Mark Gilbert; Mark Olsen; Ronald Sapiente; Brian Berkey; Minesh Mehta
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-20       Impact factor: 3.333

Review 8.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

9.  Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia.

Authors:  Noriko Usui; Nobuaki Dobashi; Osamu Asai; Shingo Yano; Yuichi Yahagi; Takeshi Saito; Yuko Yamaguchi; Kinuyo Kasama; Yutaka Okawa; Naohiro Sekiguchi; Yutaka Takei; Katsuki Sugiyama; Yoji Ogasawara; Hiroko Ohtsubo; Ken Kaito; Masayuki Kobayashi
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

10.  Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

Authors:  Paul M Harari; Jonathan Harris; Merrill S Kies; Jeffrey N Myers; Richard C Jordan; Maura L Gillison; Robert L Foote; Mitchell Machtay; Marvin Rotman; Deepak Khuntia; William Straube; Qiang Zhang; Kian Ang
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.